OncoMatch/Clinical Trials/NCT06810791

HVA vs IA/DA or VA in the Treatment of ND HR-AML

Is NCT06810791 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including HVA and VA for newly diagnosed acute myeloid leukemia with high risk.

Phase 3RecruitingNanfang Hospital, Southern Medical UniversityNCT06810791Data as of May 2026

Treatment: HVA · VA · Standard Chemotherapy — The aim of this study is to evaluate the safety and efficacy of homohartonine combined with venetoclax and azacitidine (HVA) versus intensive chemotherapy (IA/DA) or venetoclax combined with azacitidine (VA) in newly diagnosed high-risk AML patients.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Performance status

ECOG 0–3(Limited self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: anti-aml therapy

Exception: leukopenia therapy, such as hydroxyurea or cytarabine < 1.0g/d

Lab requirements

Kidney function

creatinine clearance acuity 30 ml/min

Liver function

alt < 5 times normal value, bilirubin < 3 times normal value

Cardiac function

cardiac function > level 2 [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify